Advances in Genetic Medicines: Approved Therapies in CRISPR, Gene Therapies, and Oligos
- HMX
Start Today Register and begin immediately.
Dive into the mechanisms of action and exciting applications of new FDA-approved genetic medicines.
- Online; Self-Paced
Enroll and gain access to course materials to complete at your own pace.
Certificate
Earn a short course certificate of completion when you finish all coursework within 8 weeks.
3-4 Hours
Most people can expect to complete short courses in 3-4 hours.
On This Page
Overview
While the molecular basis of many genetic diseases has been understood for decades, our ability to treat them has progressed more slowly. Genetic medicines are an emerging class of diverse therapeutics that are changing this landscape by offering new strategies for targeting the underlying mechanisms of disease. With each new approval, genetic medicines are supplying the tools that researchers, clinicians, and developers need to expand the number of druggable targets and treat more conditions, including those once considered untreatable.
This advanced HMX short course offers a unique way for professionals to learn from Harvard Medical School faculty and industry experts at the forefront of genetic medicine. Whether you are new to the field or seeking to advance your expertise, you will gain relevant, practical insights into recently FDA-approved therapies, including small interfering RNAs, antisense oligonucleotides, gene therapies, and gene editing technologies. You will examine how these therapies are designed and delivered to specific tissues to treat various genetic diseases, as well as learn about the clinical data that led to their approval. You will also explore practical concerns, such as the importance of patient choice and the issues of navigating regulatory considerations.
By the end of this course, you will be equipped with a strong understanding of relevant genetic medicines and the promise of this exciting field.
Learning Objectives
- Examine how various genetic medicines are delivered to specific tissues—such as the liver, nervous system, eye, skin, and muscle—to treat disease.
- Understand how the pathophysiology of each disease shapes the choice of therapeutic approach.
- Acquire an in-depth understanding of the current landscape of genetic medicines, including recent advancements and key challenges.
Participant Types
Clinicians and other health care professionals, professionals in the biopharmaceutical or related industries, biomedical researchers, professors, or academics in genetics or related fields.
About the Course
HMX short courses feature targeted lessons on the latest medical science topics and advancements. Stay up to date on essential knowledge in a format designed to fit your busy schedule.
Who Should Enroll
This course will benefit:
- Clinicians and other health care professionals who are keen to explore how recent approvals in genetic medicines could have practical implications for patient care.
- Professionals in the biopharmaceutical or related industries who are seeking to understand the unique capabilities, applications, and advantages of new genetic therapies.
- Biomedical researchers, professors, or academics in genetics or related fields who are interested in learning how the latest developments in genetic medicine could influence their research or teaching.
Course Format
Most people can expect to spend 3-4 hours total on an HMX short course. To be considered for a short course certificate of completion, you must complete your coursework within eight weeks.
Group Enrollments
HMX courses are ideal for organizations looking to train teams or larger groups. Group pricing is available, making it a cost-effective investment in team development.
Faculty
HMX courses are led by Harvard Medical School faculty, working in collaboration with a multi-disciplinary team of experts in biomedical visualization, assessment, and the science of learning to create a unique learning experience that will stay with you.
Caity Anderson
PhD
- Lecturer in Genetics, Harvard Medical School
- Associate Director of HMX Curriculum
Maire Jung
PhD
- Vice President & Chief Scientific Officer, RNA Lilly Institute of Genetic Medicine, Eli Lilly and Company
Art Krieg, MD
Professor, RNA Therapeutics Institute, UMass Chan Medical School
Founder and former CSO, Checkmate Pharmaceuticals, Inc.
From Our Learners
“You’re learning from the best people in that field, all from the computer and you can do it at your own pace at home, which I think is really awesome for [a nurse] like me.”
Request Information
Interested in learning more about this program? Sign up for details.